一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 广州
公开的入选条件
- 1. Written informed consent for all study according to local regulatory requirements prior to beginning specific protocol procedures
- 2. Female patients, age ≥ 18 years
- 3. Histologically confirmed unilateral primary carcinoma of the breast, except for occult breast cancer, inflammatory breast cancer without assessable focus or eczema like breast cancer
- 4. HER2-low-positive (defined here as HER2 IHC 2+ and FISH-) and HR positive(defined here as ER and/or PR \>1% stained cells)
- 5. Tumour greater than 2 cm diameter or histologically (core- or fine-needle biopsy) involved lymph nodes
- 6. According to RECIST version 1.1, there is at least one evaluable target lesion
- 7. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1
- 8. Required laboratory values including following parameters: WBC count:≥3.0 x 10\^9/L ; ANC: ≥ 1.5 x 10\^9/L; Platelet count: ≥ 100 x 10\^9/L; Hemoglobin: ≥ 9.0 g/dL; Total bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤ 2.5 x ULN; alkaline pho
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05165225；登记信息更新于 2026-09-16。